Nanordica Medical is an Estonian medtech company founded by scientists and medical doctors, dedicated to transforming laboratory innovations into practical medical solutions. We focus on the development of first-in-class nanotechnology-based antibacterial wound care products based on Premotiv technology. Several of Nanordica’s activities have been supported by the Estonian Business and Innovation Agency (EIS). Currently, three applied research projects are underway, with the aim of establishing a scientific and technological foundation for the development of even more effective wound care solutions in the future.

​​​

• Project RE.5.04.23-0466 “Development of first-in-class products for enhanced wound healing” (total budget EUR 1,656,891) is focused on the development of a new generation of wound care products. The objective of the project is to create first-in-class products that accelerate wound healing, reduce the risk of infection, and support the body’s natural healing processes. During the study, new material solutions and technologies are developed and tested both under laboratory conditions and in accordance with regulatory requirements. As a result of the project, prototypes will be completed, creating a basis for bringing new products to market.

​​

• The project “Mechanisms of action of an innovative antibacterial wound dressing” (2021–2027.1.01.24-0777; EUR 98,101.92) is implemented under the Intersectoral Mobility Measure (SekMo). Within the framework of the project, Jekaterina Krištal, PhD, who recently completed her postdoctoral research at the University of Helsinki, Finland, was recruited to the company. The aim of the project is to conduct applied research to investigate the mechanisms of action of Nanordica’s innovative wound dressing. The study will provide knowledge on how the different components of Premotive nanotechnology influence the wound healing process. This creates a basis for strengthening the value proposition of the existing product and for the development of new products. The knowledge gained enables more targeted and evidence-based product development and increases trust among healthcare professionals and patients.

​​

• The project “Impact of physicochemical properties of materials on the functionality of wound dressings” (2021–2027.1.01.24-1242; total budget EUR 98,286.83) is also implemented under the Intersectoral Mobility Measure (SekMo). Within the project, Sten Miller, PhD, who recently completed his doctoral studies at the National Institute of Chemical Physics and Biophysics, was recruited to the company. The project focuses on investigating the relationships between the properties of wound dressings and their performance. The applied research examines how properties such as for example moisture regulation and hydrophobicity affect the ability of dressings to bind bacteria and absorb wound exudate. The results of the study provide a scientific basis for the development of prototypes with improved properties and for their initial regulatory testing.​​

​

​All three projects contribute to the development of science-intensive medical technology in Estonia and help ensure that even more effective and safer wound care solutions will reach the market in the future.

​